{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T16:01:38Z","timestamp":1781971298943,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,19]],"date-time":"2014-07-19T00:00:00Z","timestamp":1405728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s11011-014-9587-3","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T21:29:33Z","timestamp":1405632573000},"page":"107-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics?"],"prefix":"10.1007","volume":"30","author":[{"given":"Esther Ching-Lan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Ju","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaofen","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-Band","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,19]]},"reference":[{"key":"9587_CR1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00002018-200629070-00004","volume":"29","author":"W Aichhorn","year":"2006","unstructured":"Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J (2006) Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 29:587\u2013598","journal-title":"Drug Saf"},{"key":"9587_CR2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KG Alberti","year":"2006","unstructured":"Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome\u2013a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23:469\u2013480","journal-title":"Diabet Med"},{"key":"9587_CR3","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association","year":"2004","unstructured":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596\u2013601","journal-title":"Diabetes Care"},{"key":"9587_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.014","volume":"111","author":"YM Bai","year":"2009","unstructured":"Bai YM, Chen TT, Yang WS, Chi YC, Lin CC, Liou YJ, Wang YC, Su TP, Chou P, Chen JY (2009) Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 111:1\u20138","journal-title":"Schizophr Res"},{"key":"9587_CR5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/WNF.0b013e31824d5288","volume":"35","author":"R Bou Khalil","year":"2012","unstructured":"Bou Khalil R (2012) Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Clin Neuropharmacol 35:141\u2013147","journal-title":"Clin Neuropharmacol"},{"key":"9587_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.apnu.2008.06.007","volume":"23","author":"S Brunero","year":"2009","unstructured":"Brunero S, Lamont S, Fairbrother G (2009) Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. Arch Psychiatr Nurs 23:261\u2013268","journal-title":"Arch Psychiatr Nurs"},{"key":"9587_CR7","first-page":"611","volume":"67","author":"SY Chuang","year":"2004","unstructured":"Chuang SY, Chen CH, Chou P (2004) Prevalence of metabolic syndrome in a large health check-up population in Taiwan. J Chin Med Assoc 67:611\u2013620","journal-title":"J Chin Med Assoc"},{"key":"9587_CR8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.109.066217","volume":"196","author":"NA Crossley","year":"2010","unstructured":"Crossley NA, Constante M, McGuire P, Power P (2010) Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196:434\u2013439","journal-title":"Br J Psychiatry"},{"key":"9587_CR9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","volume":"101","author":"M Hert De","year":"2008","unstructured":"De Hert M, Schreurs V, Sweers K (2008) Typical and second-generation antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 101:295\u2013303","journal-title":"Schizophr Res"},{"key":"9587_CR10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","volume":"8","author":"M Hert De","year":"2009","unstructured":"De Hert M, Schreurs V, Vancampfort D, van Winkel R (2009) Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8:15\u201322","journal-title":"World Psychiatry"},{"key":"9587_CR11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","volume":"194","author":"E Fernandez-Egea","year":"2009","unstructured":"Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, Esmatjes E, Garcia-Rizo C, Kirkpatrick B (2009) Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 194:434\u2013438","journal-title":"Br J Psychiatry"},{"key":"9587_CR12","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1253\/circj.CJ-13-0786","volume":"77","author":"J Hata","year":"2013","unstructured":"Hata J, Kiyohara Y (2013) Epidemiology of stroke and coronary artery disease in Asia. Circ J 77:1923\u20131932","journal-title":"Circ J"},{"key":"9587_CR13","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1253\/circj.CJ-09-0264","volume":"73","author":"A Higashiyama","year":"2009","unstructured":"Higashiyama A, Okamura T, Ono Y, Watanabe M, Kokubo Y, Okayama A (2009) Risk of smoking and metabolic syndrome for incidence of cardiovascular disease. Comparison of relative contribution in urban Japanese population: the Suita study. Circ J 73:2258\u20132263","journal-title":"Circ J"},{"key":"9587_CR14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0269881105056647","volume":"20","author":"H Hosojima","year":"2006","unstructured":"Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, Kanai A, Kase A, Uchikado H, Hirayasu Y (2006) Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20:75\u201379","journal-title":"J Psychopharmacol"},{"key":"9587_CR15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2310\/JIM.0b013e318182080a","volume":"56","author":"J Huang","year":"2008","unstructured":"Huang J, Parish R, Mansi I, Yu H, Kennen EM, Davis T, Carden D (2008) Non-high-density lipoprotein cholesterol in patients with metabolic syndrome. J Investig Med 56:931\u2013936","journal-title":"J Investig Med"},{"key":"9587_CR16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1600-0447.2009.01401.x","volume":"120","author":"MC Huang","year":"2009","unstructured":"Huang MC, Lu ML, Tsai CJ, Chen PY, Chiu CC, Jian DL, Lin KM, Chen CH (2009) Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 120:274\u2013280","journal-title":"Acta Psychiatr Scand"},{"key":"9587_CR17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0929-6646(09)60161-3","volume":"105","author":"LC Hwang","year":"2006","unstructured":"Hwang LC, Bai CH, Chen CJ (2006) Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 105:626\u2013635","journal-title":"J Formos Med Assoc"},{"key":"9587_CR18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1744-6163.2006.00073.x","volume":"42","author":"NL Keltner","year":"2006","unstructured":"Keltner NL (2006) Metabolic syndrome: schizophrenia and second-generation antipsychotics. Perspect Psychiatr Care 42:204\u2013207","journal-title":"Perspect Psychiatr Care"},{"key":"9587_CR19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1471-244X-11-173","volume":"11","author":"S Kraemer","year":"2011","unstructured":"Kraemer S, Minarzyk A, Forst T, Kopf D, Hundemer HP (2011) Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3\u00a0months of treatment with antipsychotics: results from a German observational study. BMC Psychiatr 11:173","journal-title":"BMC Psychiatr"},{"key":"9587_CR20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/JCP.0b013e31818ce71f","volume":"28","author":"E Lee","year":"2008","unstructured":"Lee E, Leung CM (2008) Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone. J Clin Psychopharmacol 28:707\u20139","journal-title":"J Clin Psychopharmacol"},{"key":"9587_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19\u201332","journal-title":"Schizophr Res"},{"key":"9587_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19:1\u201393","journal-title":"CNS Drugs"},{"issue":"Suppl 4","key":"9587_CR23","first-page":"8","volume":"68","author":"JW Newcomer","year":"2007","unstructured":"Newcomer JW (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68(Suppl 4):8\u201313","journal-title":"J Clin Psychiatry"},{"key":"9587_CR24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5551\/jat.1016","volume":"17","author":"H Noda","year":"2010","unstructured":"Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Ohta H (2010) Association between non-high-density lipoprotein cholesterol concentrations and mortality from coronary heart disease among Japanese men and women: the Ibaraki prefectural health study. J Atheroscler Thromb 17:30\u201336","journal-title":"J Atheroscler Thromb"},{"key":"9587_CR25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2045125312464385","volume":"3","author":"E Papanastasiou","year":"2013","unstructured":"Papanastasiou E (2013) The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol 3:33\u201351","journal-title":"Ther Adv Psychopharmacol"},{"key":"9587_CR26","doi-asserted-by":"crossref","first-page":"e46365","DOI":"10.1371\/journal.pone.0046365","volume":"7","author":"S Rampal","year":"2012","unstructured":"Rampal S, Mahadeva S, Guallar E, Bulgiba A, Mohamed R, Rahmat R, Arif MT, Rampal L (2012) Ethnic differences in the prevalence of metabolic syndrome: results from a multi-ethnic population-based survey in Malaysia. PLoS One 7:e46365","journal-title":"PLoS One"},{"key":"9587_CR27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","volume":"123","author":"C Rummel-Kluge","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225\u2013233","journal-title":"Schizophr Res"},{"key":"9587_CR28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4088\/JCP.v66n0503","volume":"66","author":"KM Saari","year":"2005","unstructured":"Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, Savolainen MJ, Koponen HJ (2005) A 4-fold risk of metabolic syndrome in patients with schizophrenia: the northern Finland 1966 birth cohort study. J Clin Psychiatry 66:559\u2013563","journal-title":"J Clin Psychiatry"},{"key":"9587_CR29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2007.05.036","volume":"95","author":"S Saddichha","year":"2007","unstructured":"Saddichha S, Ameen S, Akhtar S (2007) Incidence of new onset metabolic syndrome with second-generation antipsychotics in first episode schizophrenia: a 6-weeks prospective study in Indian female patients. Schizophr Res 95:247","journal-title":"Schizophr Res"},{"key":"9587_CR30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1078390309350918","volume":"16","author":"MV Seeman","year":"2010","unstructured":"Seeman MV (2010) Schizophrenia: women bear a disproportionate toll of antipsychotic side effects. J Am Psychiatr Nurses Assoc 16:21\u201329","journal-title":"J Am Psychiatr Nurses Assoc"},{"key":"9587_CR31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MED.0b013e32835ed9cb","volume":"20","author":"A Sniderman","year":"2013","unstructured":"Sniderman A, Kwiterovich PO (2013) Update on the detection and treatment of atherogenic low-density lipoproteins. Curr Opin Endocrinol Diabetes Obes 20:140\u2013147","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"9587_CR32","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","volume":"168","author":"TS Stroup","year":"2011","unstructured":"Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA, Network ST (2011) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168:947\u2013956","journal-title":"Am J Psychiatry"},{"key":"9587_CR33","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10398560701636906","volume":"15","author":"S Tirupati","year":"2007","unstructured":"Tirupati S, Chua LE (2007) Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas Psychiatry 15:470\u2013473","journal-title":"Australas Psychiatry"},{"key":"9587_CR34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1176\/appi.ajp.2007.07020233","volume":"164","author":"G Venkatasubramanian","year":"2007","unstructured":"Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, Shetty KT (2007) Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 164:1557\u20131560","journal-title":"Am J Psychiatry"},{"key":"9587_CR35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1179\/1743132813Y.0000000206","volume":"35","author":"J Wu","year":"2013","unstructured":"Wu J, Chen S, Liu L, Gao X, Zhou Y, Wang C, Zhang Q, Wang A, Hussain M, Sun B, Wu S, Zhao X (2013) Non-high-density lipoprotein cholesterol vs low-density lipoprotein cholesterol as a risk factor for ischemic stroke: a result from the KAILUAN study. Neurol Res 35:505\u2013511","journal-title":"Neurol Res"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-014-9587-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-014-9587-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-014-9587-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T22:22:03Z","timestamp":1559341323000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-014-9587-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,19]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["9587"],"URL":"https:\/\/doi.org\/10.1007\/s11011-014-9587-3","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,19]]}}}